These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22041125)

  • 21. Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington's disease.
    Ribeiro FM; Paquet M; Ferreira LT; Cregan T; Swan P; Cregan SP; Ferguson SS
    J Neurosci; 2010 Jan; 30(1):316-24. PubMed ID: 20053912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
    Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
    Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies.
    Brito V; Puigdellívol M; Giralt A; del Toro D; Alberch J; Ginés S
    Cell Death Dis; 2013 Apr; 4(4):e595. PubMed ID: 23598407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
    Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
    Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FK506 ameliorates cell death features in Huntington's disease striatal cell models.
    Rosenstock TR; de Brito OM; Lombardi V; Louros S; Ribeiro M; Almeida S; Ferreira IL; Oliveira CR; Rego AC
    Neurochem Int; 2011 Oct; 59(5):600-9. PubMed ID: 21703318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FGF9 induces neurite outgrowth upon ERK signaling in knock-in striatal Huntington's disease cells.
    Yusuf IO; Chen HM; Cheng PH; Chang CY; Tsai SJ; Chuang JI; Wu CC; Huang BM; Sun HS; Chen CM; Yang SH
    Life Sci; 2021 Feb; 267():118952. PubMed ID: 33383048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altered microRNAs in STHdh(Q111)/Hdh(Q111) cells: miR-146a targets TBP.
    Sinha M; Ghose J; Das E; Bhattarcharyya NP
    Biochem Biophys Res Commun; 2010 Jun; 396(3):742-7. PubMed ID: 20451497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of nuclear REST by alternative splicing: a potential therapeutic target for Huntington's disease.
    Chen GL; Ma Q; Goswami D; Shang J; Miller GM
    J Cell Mol Med; 2017 Nov; 21(11):2974-2984. PubMed ID: 28524599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.
    Saavedra A; Giralt A; Rué L; Xifró X; Xu J; Ortega Z; Lucas JJ; Lombroso PJ; Alberch J; Pérez-Navarro E
    J Neurosci; 2011 Jun; 31(22):8150-62. PubMed ID: 21632937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
    Stratford AL; Fry CJ; Desilets C; Davies AH; Cho YY; Li Y; Dong Z; Berquin IM; Roux PP; Dunn SE
    Breast Cancer Res; 2008; 10(6):R99. PubMed ID: 19036157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease.
    Quintanilla RA; Jin YN; Fuenzalida K; Bronfman M; Johnson GVW
    J Biol Chem; 2008 Sep; 283(37):25628-25637. PubMed ID: 18640979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of NHE3 by lysophosphatidic acid is mediated by phosphorylation of NHE3 by RSK2.
    No YR; He P; Yoo BK; Yun CC
    Am J Physiol Cell Physiol; 2015 Jul; 309(1):C14-21. PubMed ID: 25855080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease.
    Pineda JR; Pardo R; Zala D; Yu H; Humbert S; Saudou F
    Mol Brain; 2009 Oct; 2():33. PubMed ID: 19860865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Exogenous NUB1 Expression in the Striatum of HDQ175/Q7 Mice.
    Vodicka P; Chase K; Iuliano M; Valentine DT; Sapp E; Lu B; Kegel-Gleason KB; Sena-Esteves M; Aronin N; DiFiglia M
    J Huntingtons Dis; 2016 Jun; 5(2):163-74. PubMed ID: 27314618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 14-3-3beta is a p90 ribosomal S6 kinase (RSK) isoform 1-binding protein that negatively regulates RSK kinase activity.
    Cavet ME; Lehoux S; Berk BC
    J Biol Chem; 2003 May; 278(20):18376-83. PubMed ID: 12618428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Twist1 Plays an Anti-apoptotic Role in Mutant Huntingtin Expression Striatal Progenitor Cells.
    Jen WP; Chen HM; Lin YS; Chern Y; Lee YC
    Mol Neurobiol; 2020 Mar; 57(3):1688-1703. PubMed ID: 31813126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glutamate transporter expression and function in a striatal neuronal model of Huntington's disease.
    Petr GT; Bakradze E; Frederick NM; Wang J; Armsen W; Aizenman E; Rosenberg PA
    Neurochem Int; 2013 Jun; 62(7):973-81. PubMed ID: 23507328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Actin Dysfunction Induces Cell Cycle Delay at G2/M with Sustained ERK and RSK Activation in IMR-90 Normal Human Fibroblasts.
    Shrestha D; Choi D; Song K
    Mol Cells; 2018 May; 41(5):436-443. PubMed ID: 29754473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.
    Martin E; Betuing S; Pagès C; Cambon K; Auregan G; Deglon N; Roze E; Caboche J
    Hum Mol Genet; 2011 Jun; 20(12):2422-34. PubMed ID: 21493629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibroblast growth factor 9 activates anti-oxidative functions of Nrf2 through ERK signalling in striatal cell models of Huntington's disease.
    Yusuf IO; Chen HM; Cheng PH; Chang CY; Tsai SJ; Chuang JI; Wu CC; Huang BM; Sun HS; Yang SH
    Free Radic Biol Med; 2019 Jan; 130():256-266. PubMed ID: 30391672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.